CymitQuimica logo

DOTA-(Tyr3)-Octreotate acetate salt

CAS:

Ref. 3D-FD109795

1mg
428.00€
2mg
583.00€
5mg
849.00€
10mg
1,213.00€
25mg
1,981.00€
DOTA-(Tyr3)-Octreotate acetate salt
Biosynth

Product Information

Name:DOTA-(Tyr3)-Octreotate acetate salt
Controlled Product
Synonyms:
  • DOTATATE
  • DOTA-(Tyr³,Thr⁸)-Octreotide
  • DOTA-[Tyr3] Octreotide Acid (Octreotate)
Brand:Biosynth
Description:Octreotate is a radiopharmaceutical that is synthesized by reacting DOTA-Tyr3 with octreotide acetate. Octreotate, also known as dotatate, is used in nuclear medicine to treat neuroendocrine tumours. This drug has a high yield and can be reliably prepared using cassettes and computerised equipment to create germanium-68 labelled octreotate. The radionuclide emits positrons and gamma rays, which are used for imaging neuroendocrine tumours in the brain or other organs. Octreotate is a synthetic analogue of the natural hormone octreotide, which binds to receptors on the cell surface and prevents the release of hormones from cells. This may be due to its ability to inhibit protein synthesis by inhibiting rRNA synthesis.
Notice:Our products are intended for lab use only. For any other use, please contact us.

Chemical properties

Molecular weight:1,435.63 g/mol
Formula:C65H90N14O19S2
Purity:Min. 95 Area-%
Color/Form:White Slightly Yellow Powder

Technical inquiry about: DOTA-(Tyr3)-Octreotate acetate salt

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
◻️
CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
* Mandatory fields.